Reference | Study period | Inclusion criteria | No. of S. aureus | No. of MRSA (%) | MRSA clone |
[12] | 2004-2009 | Hospitalized patients’ skin and soft tissue samples had cultures obtained (Martinique) | Data not reported | 69 | Martinique CC8-MRSA-IV “Lyone” (50.7%) CC8-MRSA-IV “UK-EMRSA” (7.2%) ST8-MRSA-IV “USA300” (7.2%) ST8-MRSA-IV ACME− (1.45%) WA-MRSA-62 PVL− (1.45%) ST239-MRSA-III “Brazillian” (1.45%) ST72-MRSA-IV “USA700” (1.45%) CC59 ST59-MRSA-V (1.45%) CC5 ST5-MRSA-I “Geraldine” (13%) CC5-MRSA-IV “pediatric” (4.3%) CC5-MRSA-IV “pediatric” PVL− (1.45%) CC80-MRSA-IV PVL− “European CA-MRSA” (10%) Jamaica ST8-MRSA-IV “USA300” (6.25%) ST5/ST225-MRSA-II New York-Japan (12.5%) Trinidad ST8-MRSA-IV “USA300” (6.25%) ST239-MRSA-III “Brazillian” (18.75%) CC5-MRSA-IV “pediatric” (6.25%) Tobago ST8-MRSA-IV “USA300” (12.5%) ST239-MRSA-III “Brazillian” (12.5%) WA-MRSA-62 PVL− (6.25%) Guadeloupe ST8-MRSA-IV “USA300” (6.25%) WA-MRSA-62 PVL− (6.25%) CC5 ST5-MRSA-I “Geraldine” (6.25) |
2010-2011 | Hospitalized patients’ skin and soft tissue samples had cultures obtained (Trinidad, Tobago, Jamaica, Guadeloupe) | Data not reported | 16 | ||
[11] | 2014-2015 | Hospitalized patients’ blood, bone, ear, fluids, surgical drains, tissue, urine and wounds had culture obtained | Data not reported | 100 | CA-MRSA PVL+ (76%) CA-MRSA PVL− (14%) HA-MRSA, PVL+ (9%) HA-MRSA, PVL− (1%) CA-MRSA, PVL+ (95.9%) CA-MRSA, spa+, mecA+ (4.1%) CA-MRSA, spa+, mecA+ resistant to vancomycin (2.07%) |
2013-2016 | Outpatients’ convenience samples from wounds, nasal, penile and vaginal had culture obtained | Data not reported | 193 | ||
[19] | 2008 | Hospitalized patients’ surgical wounds, bronchial/tracheal aspirations, blood, skin, abdominal drainage and chest tissue biopsy had culture obtained | 68 | 40 (58.9) | Spa-types t149 (60%) CC8 t008 (20%), PVL+ t037 (15%), t4088 (2.5) t2029 (2.5%) |